| Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis R Marsh, H Gavillet, L Hanson, C Ng, M Mitchell-Whyte, G Major, ... Journal of Cystic Fibrosis 21 (3), 506-513, 2022 | 26 | 2022 |
| Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome R Marsh, C Dos Santos, L Hanson, C Ng, G Major, AR Smyth, D Rivett, ... Microbiology Spectrum 11 (5), e01175-23, 2023 | 8 | 2023 |
| Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis R Marsh, C Dos Santos, A Yule, NS Dellschaft, CL Hoad, C Ng, G Major, ... Journal of Cystic Fibrosis 23 (5), 967-976, 2024 | 2 | 2024 |
| P116 Effects of SymkeviTM (tezacaftor/ivacaftor) on the lung and gut microbiota in cystic fibrosis R Marsh, L Hanson, C Ng, M Mitchell-Whyte, N Dellschaft, C Hoad, ... Journal of Cystic Fibrosis 21, S97, 2022 | 1 | 2022 |
| Persistent intestinal abnormalities and symptoms in cystic fibrosis: The underpinning mechanisms impacting gut health and motility. Protocol for a systematic review RJ Marsh, C Ng, G Major, DW Rivett, A Smyth, CJ van der Gast medRxiv, 2020.07. 13.20144808, 2020 | 1 | 2020 |
| P320 Impact of extended elexacaftor/tezacaftor/ivacaftor therapy on the gut microbiome in cystic fibrosis R Marsh, C Dos Santos, A Yule, NS Dellschaft, CL Hoad, C Ng, G Major, ... Journal of Cystic Fibrosis 23, S166-S167, 2024 | | 2024 |
| The organisation and function of the gut microbiota in cystic fibrosis R Marsh Manchester Metropolitan University, 2024 | | 2024 |
| 565 Relationships between tezacaftor/ivacaftor administration, gut microbiota composition, and intestinal function in cystic fibrosis R Marsh, L Hanson, C Ng, M Mitchell-Whyte, N Dellschaft, C Hoad, ... Journal of Cystic Fibrosis 21, S314-S315, 2022 | | 2022 |
| 465: Intestinal function and transit relates to microbial dysbiosis in the CF gut R Marsh, H Gavillet, L Hanson, C Ng, G Major, A Smyth, D Rivett, ... Journal of Cystic Fibrosis 20, S220, 2021 | | 2021 |